Joff Wild, IAM Magazine | 22 Sep 2014 | Read Blog
Joff Wild, IAM Magazine | 21 Sep 2014 | Read Blog
Jack Ellis, IAM Magazine | 19 Sep 2014 | Read Blog
The United States lacks a strong
framework for protecting trade secrets
at the federal level. However, proposed
legislation could be about to shake things
up and provide new protection in this area
Collective rights management organisations wield considerable power: they make claims for the unauthorised performance of music, collect remuneration for the public performance and pay that remuneration to the relevant performer. This business model worked smoothly until recently, when the High Commercial Court issued a ruling that complicates this process.
The High Court has decided that Genentech’s patent relating to a dosage regimen for Herceptin is invalid. This judgment highlights the importance of meeting the requirements for sufficient disclosure for claims based on dosage regimens and the difficulty of obtaining the information required in clinical trials.
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.